Press Releases

Press Releases

MPIB-Emeritus Axel Ullrich is awarded with Lasker Award 2019

Axel Ullrich, together with H. Michael Shepard and Dennis J. Slamon, receives the highest biomedical scientific award in the United States for the invention of Herceptin. more

<div style="text-align: left;" align="center">Stopping cancer at the root: Axel Ullrich named European Inventor Award 2017 finalist</div>

Cancer remains one of the leading causes of death worldwide and the World Health Organisation projects over 13 million annual deaths from cancer by the year 2030. A new generation of medicines based on genetic engineering stops cancer at the root, by disrupting the blood supply or the growth of tumours. Key insights behind this new approach are owed to German molecular biologist Axel Ullrich (73). In a research career spanning over four decades, the pioneer identified the cellular processes behind the genesis of cancer and other diseases. In commercial drug development roles and as a leading Max Planck Institute researcher, Ullrich spearheaded ground-breaking laboratory techniques and next-generation anti-cancer medicines. For these achievements, Axel Ullrich has been nominated for the European Inventor Award 2017 as one of three finalists in the category "Lifetime Achievement". The winners of the 12th edition of the European Patent Office (EPO)’s annual innovation prize will be announced at a ceremony in Venice on 15 June. more

<p style="text-align: left;" align="center">Johann-Georg-Zimmermann Medal for Axel Ullrich</p>

Axel Ullrich, Professor Emeritus of the Department of Molecular Biology at the Max Planck Institute of Biochemistry in Martinsried has been awarded the Johann-Georg-Zimmermann Medal for his services in the field of cancer research. For more than 40 years the award, sponsored by Deutsche Hypothekenbank AG, has recognized outstanding scientists in the field of cancer research. The MHHplus Foundation will present the award at Hannover Medical School on 6 February 2017. more

<p style="text-align: left;" align="center">Gene variation promotes uncontrolled cell division</p>

Mom’s eyes and dad’s tumor? Cancer is due to genetic defects, some of which can be hereditary. The gene variant rs351855, for example, occurs in one in two cancer patients. It supports the growth of a variety of tumors that are aggressive and difficult to treat. A team headed by Axel Ullrich from the Max Planck Institute of Biochemistry in Martinsried identified the gene variant a decade ago. The same laboratory has now succeeded for the first time in showing that the defect exposes an otherwise hidden binding site on the FGFR4 receptor. In a previously unknown interaction, growth factor STAT3, which promotes cancer, binds to the exposed site. The STAT3 signaling cascade can be efficiently blocked. For the first time, this could provide a promising therapeutic approach for many cancer patients. At the same time, it represents an important step towards personalized medicine. The paper was published in Nature. more

Anticancer Substances Clear Next Hurdle - Licensing Agreement Signed by the Max Planck Institute of Biochemistry, Lead Discovery Center GmbH and the Qurient Company

Most cancer patients die of the disease because tumor cells spread to other sites in the body and form new tumors, so-called metastases. Scientists of the Max Planck Institute (MPI) of Biochemistry in Martinsried and their cooperation partners of the Lead Discovery Center GmbH (LDC) have now signed a licensing agreement with the Korean company Qurient for a group of active substances that have been a focus of their research for a long time. These substances shall target metastasizing and drug-resistant tumors more specifically and selectively. Qurient will successively enter the tested substances into preclinical and clinical trials in order to use them in the future for drugs in patients. The Max Planck researchers hope that if the experiments and clinical trials are successful, a drug based on the new active substances could be on the market by the end of the decade.


Show more
Go to Editor View